GlassScriptPhysician profile
Margaret M Devault
NPI 1598784209
$5,663.35
in general payments reported to CMS, 2019-2025
29 companies · $759 in 2025
The $759 reported for 2025 was more than what 86% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $1,614 · 2023: $1,005 · 2024: $1,380 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.46 |
| Education | $181.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $463.55 | 2022-2025 | Veozah |
| Shield Therapeutics INC | $458.31 | 2023-2025 | Accrufer |
| Abbvie INC. | $422.20 | 2021-2024 | |
| Agile Therapeutics, INC. | $397.03 | 2021-2024 | Twirla |
| Mayne Pharma Commercial LLC | $340.89 | 2021-2025 | |
| Pfizer INC. | $316.33 | 2021-2024 | |
| Novo Nordisk INC | $310.64 | 2021-2025 | Wegovy |
| Amgen INC. | $296.49 | 2021-2024 | Evenity, Prolia |
| Exeltis, USA INC. | $271.19 | 2021-2025 | Slynd |
| Currax Pharmaceuticals LLC | $267.76 | 2021-2024 | Contrave, Onzetra Xsail, Nexletol |
| Organon LLC | $218.72 | 2021-2025 | Nexplanon, Nuvaring |
| Aspira Women'S Health INC | $218.69 | 2022 | |
| Coopersurgical, INC. | $204.63 | 2021-2025 | Paragard T 380a, Paragard T 380a, Ally II Ups |
| Therapeuticsmd, INC. | $199.26 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $164.68 | 2024-2025 | Myfembree, Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $160.11 | 2023-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Millicent US INC | $148.36 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Merck Sharp & Dohme LLC | $140.30 | 2021-2025 | Gardasil 9, Gardasil |
| Radius Health, INC. | $133.63 | 2022-2023 | |
| Exact Sciences Corporation | $128.45 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $122.30 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $97.72 | 2021-2023 | |
| Avion Pharmaceuticals | $51.55 | 2021-2023 | Balcoltra |
| Scynexis, INC. | $41.78 | 2022 | |
| Axonics, INC. | $21.17 | 2023 | Axonics |
| Teleflex LLC | $21.10 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.55 | 2024 | |
| Evofem Biosciences, INC. | $16.80 | 2021 | |
| Boston Scientific Corporation | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Devault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.